Novel congenital myasthenic syndromes associated with defects in quantal release

Margherita Milone, T. Fukuda, X. M. Shen, A. Tsujino, J. Brengman, Andrew G Engel

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Most congenital myasthenic syndromes are caused by defects in postsynaptic or synaptic basal lamina-associated proteins; congenital myasthenic syndromes (CMSs) associated with presynaptic defects are uncommon. Here, the authors describe clinical, electrophysiologic, and morphologic features of two novel and highly disabling CMSs, one determined by presynaptic and the other determined by combined presynaptic and postsynaptic defects. Methods: Microelectrode, single channel patch clamp, immunocytochemical, [ 125I]α-bungarotoxin binding, and quantitative electron microscopy studies of endplates were performed. Candidate genes were directly sequenced. Results: Patient 1, a 7-year-old boy, had severe myasthenic symptoms since infancy. Patient 2, a 48-year-old man, had delayed motor milestones and became progressively weaker after age 2 years. Both used wheelchairs and had a 30-50% EMG decrement on 2-Hz stimulation. Evoked quantal release was reduced to approximately 25% of normal in both. In Patient 2, the synaptic response to acetylcholine was further compromised by degeneration of the junctional folds with concomitant loss of the acetylcholine receptor (AChR). A search for mutations in components of the synaptic vesicle release complex and in other candidate proteins failed to identify the molecular basis of the two syndromes. Conclusions: Combined clinical, morphologic, and in vitro electrophysiologic findings define two novel congenital myasthenic syndromes. The molecular basis of these syndromes awaits discovery.

Original languageEnglish (US)
Pages (from-to)1223-1229
Number of pages7
JournalNeurology
Volume66
Issue number8
DOIs
StatePublished - Apr 2006

Fingerprint

Congenital Myasthenic Syndromes
Bungarotoxins
Wheelchairs
Synaptic Vesicles
Muscle Weakness
Microelectrodes
Cholinergic Receptors
Basement Membrane
Acetylcholine
Electron Microscopy
Proteins
Mutation
Genes

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Novel congenital myasthenic syndromes associated with defects in quantal release. / Milone, Margherita; Fukuda, T.; Shen, X. M.; Tsujino, A.; Brengman, J.; Engel, Andrew G.

In: Neurology, Vol. 66, No. 8, 04.2006, p. 1223-1229.

Research output: Contribution to journalArticle

Milone, Margherita ; Fukuda, T. ; Shen, X. M. ; Tsujino, A. ; Brengman, J. ; Engel, Andrew G. / Novel congenital myasthenic syndromes associated with defects in quantal release. In: Neurology. 2006 ; Vol. 66, No. 8. pp. 1223-1229.
@article{e0110160e466413fa27f639eec4014dc,
title = "Novel congenital myasthenic syndromes associated with defects in quantal release",
abstract = "Background: Most congenital myasthenic syndromes are caused by defects in postsynaptic or synaptic basal lamina-associated proteins; congenital myasthenic syndromes (CMSs) associated with presynaptic defects are uncommon. Here, the authors describe clinical, electrophysiologic, and morphologic features of two novel and highly disabling CMSs, one determined by presynaptic and the other determined by combined presynaptic and postsynaptic defects. Methods: Microelectrode, single channel patch clamp, immunocytochemical, [ 125I]α-bungarotoxin binding, and quantitative electron microscopy studies of endplates were performed. Candidate genes were directly sequenced. Results: Patient 1, a 7-year-old boy, had severe myasthenic symptoms since infancy. Patient 2, a 48-year-old man, had delayed motor milestones and became progressively weaker after age 2 years. Both used wheelchairs and had a 30-50{\%} EMG decrement on 2-Hz stimulation. Evoked quantal release was reduced to approximately 25{\%} of normal in both. In Patient 2, the synaptic response to acetylcholine was further compromised by degeneration of the junctional folds with concomitant loss of the acetylcholine receptor (AChR). A search for mutations in components of the synaptic vesicle release complex and in other candidate proteins failed to identify the molecular basis of the two syndromes. Conclusions: Combined clinical, morphologic, and in vitro electrophysiologic findings define two novel congenital myasthenic syndromes. The molecular basis of these syndromes awaits discovery.",
author = "Margherita Milone and T. Fukuda and Shen, {X. M.} and A. Tsujino and J. Brengman and Engel, {Andrew G}",
year = "2006",
month = "4",
doi = "10.1212/01.wnl.0000205596.19540.2c",
language = "English (US)",
volume = "66",
pages = "1223--1229",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Novel congenital myasthenic syndromes associated with defects in quantal release

AU - Milone, Margherita

AU - Fukuda, T.

AU - Shen, X. M.

AU - Tsujino, A.

AU - Brengman, J.

AU - Engel, Andrew G

PY - 2006/4

Y1 - 2006/4

N2 - Background: Most congenital myasthenic syndromes are caused by defects in postsynaptic or synaptic basal lamina-associated proteins; congenital myasthenic syndromes (CMSs) associated with presynaptic defects are uncommon. Here, the authors describe clinical, electrophysiologic, and morphologic features of two novel and highly disabling CMSs, one determined by presynaptic and the other determined by combined presynaptic and postsynaptic defects. Methods: Microelectrode, single channel patch clamp, immunocytochemical, [ 125I]α-bungarotoxin binding, and quantitative electron microscopy studies of endplates were performed. Candidate genes were directly sequenced. Results: Patient 1, a 7-year-old boy, had severe myasthenic symptoms since infancy. Patient 2, a 48-year-old man, had delayed motor milestones and became progressively weaker after age 2 years. Both used wheelchairs and had a 30-50% EMG decrement on 2-Hz stimulation. Evoked quantal release was reduced to approximately 25% of normal in both. In Patient 2, the synaptic response to acetylcholine was further compromised by degeneration of the junctional folds with concomitant loss of the acetylcholine receptor (AChR). A search for mutations in components of the synaptic vesicle release complex and in other candidate proteins failed to identify the molecular basis of the two syndromes. Conclusions: Combined clinical, morphologic, and in vitro electrophysiologic findings define two novel congenital myasthenic syndromes. The molecular basis of these syndromes awaits discovery.

AB - Background: Most congenital myasthenic syndromes are caused by defects in postsynaptic or synaptic basal lamina-associated proteins; congenital myasthenic syndromes (CMSs) associated with presynaptic defects are uncommon. Here, the authors describe clinical, electrophysiologic, and morphologic features of two novel and highly disabling CMSs, one determined by presynaptic and the other determined by combined presynaptic and postsynaptic defects. Methods: Microelectrode, single channel patch clamp, immunocytochemical, [ 125I]α-bungarotoxin binding, and quantitative electron microscopy studies of endplates were performed. Candidate genes were directly sequenced. Results: Patient 1, a 7-year-old boy, had severe myasthenic symptoms since infancy. Patient 2, a 48-year-old man, had delayed motor milestones and became progressively weaker after age 2 years. Both used wheelchairs and had a 30-50% EMG decrement on 2-Hz stimulation. Evoked quantal release was reduced to approximately 25% of normal in both. In Patient 2, the synaptic response to acetylcholine was further compromised by degeneration of the junctional folds with concomitant loss of the acetylcholine receptor (AChR). A search for mutations in components of the synaptic vesicle release complex and in other candidate proteins failed to identify the molecular basis of the two syndromes. Conclusions: Combined clinical, morphologic, and in vitro electrophysiologic findings define two novel congenital myasthenic syndromes. The molecular basis of these syndromes awaits discovery.

UR - http://www.scopus.com/inward/record.url?scp=33646696195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646696195&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000205596.19540.2c

DO - 10.1212/01.wnl.0000205596.19540.2c

M3 - Article

C2 - 16525123

AN - SCOPUS:33646696195

VL - 66

SP - 1223

EP - 1229

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 8

ER -